Athero Review - Issue 2/2020
Editorial
71
Editorial
Michal Vrablík
Personal News
72
Opustil nás profesor Milan Šamánek
Michal Vrablík
Guidelines
76
Therapy with drugs containing the active ingredient LOMITAPIDE in patients with homozygous form of familial hypercholesterolemia: a statement of the committee of the Czech Society for Atherosclerosis
Vladimír Bláha, Michal Vrablík, Vladimír Soška, Jan Piťha, Renata Cífková, Tomáš Freiberger, David Karásek, Pavel Kraml, Hana Rosolová, Tomáš Štulc, Zuzana Urbanová Za Výbor Čsat
83
How media affect fat choice
Jiří Brát
88
93
99
107
Psychosocial cardiovascular risk factors
Jan Bruthans
113
Combined hypolipidemic therapy: case report
Marcel Nesva, Patrik Christian Cmorej, David Peřan, Jaroslav Pekara
Clinical Studies
117
LipitenCliDec Study – the profile of patients with uncontrolled arterial hypertension and/or dyslipidemia in primary care in the Czech Republic: the 2nd phase results
Martin Šatný, Eva Tůmová, Michal Vrablík, Jana Mašková, Jiří Laštůvka
127
The timing for CV risk intervention as a critical success factor
Zuzana Zafarová, Michal Vrablík
131
Announcements
133
Interaktivní webinář: 1. díl – Kardiovaskulární prevence a diabetes
Kristýna Čillíková
Athero Review
2020 Issue 2
Most read in this issue
- Very low LDL cholesterol in acute coronary syndrome
- LipitenCliDec Study – the profile of patients with uncontrolled arterial hypertension and/or dyslipidemia in primary care in the Czech Republic: the 2nd phase results
- Therapy with drugs containing the active ingredient LOMITAPIDE in patients with homozygous form of familial hypercholesterolemia: a statement of the committee of the Czech Society for Atherosclerosis
- The timing for CV risk intervention as a critical success factor